1Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietie and lymphoid tissues [M]. IARC Press: Lyon,2001. 111-235.
2Harris NL,Jaffe ES,Steln H,et al, A revised European-American classification of lymphomoid nesplasms:a proposal from the International Lymphoma Study Group [J]. Blood, 1994, 84 (5):1361-1392.
5Rossi D,Galdano G. Molecular heterogeneity of diffuse large B-cell lymphoma:implieations for disease management and prognosis[J]. Hematology, 2002,7 (4) : 239-252.
6Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma:a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification[J]. Leuk Lymhoma,2002,43(1) :97-104.
8Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma:implications for disease management and prognosis. Hematology, 2002,7 (4) : 239-252.
9Hans CP,Weisenburger DD,Gascoyne RD,et al. Classification of diffuse large B-cell lymphoma into prognostically significant subgroups by immunohisto-chemistry using a tissue microarray abstract[J]. Mod Pathol, 2002,15(3) :243a.
10Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma[J]. Blood,2003,101(1):78-84.
二级参考文献9
1Osterman B, Cavallin-Stahl E, Hagberg H, et al. High-grade non-Hodgkin′s lym phoma stage I. A retrospective study of treatment, outcome and prognostic factor s in 213 patients. Acta oncol,1996,35:171-177.
2Harris NL,Jaffe ES, Diebold J et al. The World Health Organi zation classification of neoplastic diseases of the haematopoietic and lymphoid tissue. Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology,2000, 36:69-86.
3Lennert K, Feller AC. Histopathology of non-Hodgkin′s lymph oma (based on the updated Kiel classification ).Berlin:Springer-Verlag, 1992.
4Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL -6 gene in diffuse large cell non-Hodgkin′s lymphoma. Blood, 1994,83:1757-1759.
5Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl- 6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med, 1994, 331:74 -80.
6Flenghi L,Ye BH, Fizzotti M, et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am J Pathol ,19 95,147:405-411.
7Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finge r-encoding gene, BCL-6,in diffuse large-cell lymphoma. Science, 1993,262:74 7-750.
8Flenghi L, Bigerna B, Fizzotti M ,et al. Monoclonal antibodi es PG-B6a and PG-B6p recognize, respectively, a highly conserved and formol-resistant epitope on t he human BCL-6 protein amino-terminal region. Am J Pathol ,1996,148:1543-1555 .
9Carbone A, Gloghini A,Gaidano G, et al. BCL-6 protein expressi on in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood , 1997,90:2445-2450.
